Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.40 |
| ▸ | C5 | P01031 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10053114 | 0.80 | LMNA (0.42) | MAPTMEN1KMT2AACE2 | |
| SCHEMBL9463804 | 0.79 | LMNA (0.41) | MAPTMEN1KMT2A | |
| SCHEMBL15641246 | 0.79 | LMNA (0.55) | MAPTPTGS2PTGS1MEN1ABCC4 | |
| SCHEMBL29858584 | 0.79 | LMNA (0.55) | MAPTPTGS2PTGS1MEN1ABCC4 | |
| SCHEMBL838637 | 0.79 | LMNA (0.55) | MAPTPTGS2PTGS1MEN1ABCC4 | |
| SCHEMBL6927697 | 0.77 | LMNA (0.58) | MAPTMEN1KMT2AHTR2A | |
| SCHEMBL10745903 | 0.77 | TSHR (0.54) | MAPTPTGS2PTGS1MEN1ABCC4 | |
| SCHEMBL27697380 | 0.77 | PTGS2 (0.45) | MAPTPTGS2PTGS1MEN1ABCC4 | |
| SCHEMBL3051005 | 0.77 | PTGS2 (0.40) | MAPTPTGS2PTGS1MEN1ABCC4 | |
| SCHEMBL9900630 | 0.76 | PTGS2 (0.52) | MAPTPTGS2PTGS1MEN1ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255150-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255150-A1 | Novel Compounds | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B2 | MAPT 3534/4885PTGS2 790/4885PTGS1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.